Group 1 - The article lists several companies under monitoring due to stock price fluctuations, indicating potential volatility in their stock performance [1] - The monitoring periods for the companies vary, with some starting as early as August 15, 2025, and ending in early September 2025 [1] - Specific companies mentioned include *ST高鸿, 思泉新材, *ST苏吴, 赛诺医疗, 东芯股份, and 淳中科技, each with designated monitoring dates [1] Group 2 - 赛诺医疗 has two separate monitoring periods listed, indicating heightened scrutiny on its stock performance [1] - The monitoring for 东芯股份 began on July 7, 2025, suggesting earlier concerns regarding its stock activity [1] - The article does not disclose the reasons for the monitoring or the specific events leading to these actions [1]

New Stock Offerings - Shenke Co., Ltd. (002633) has an offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has an offer period from August 12, 2025, to September 10, 2025[1] - ST Gaohong (000851) has an announcement on August 26, 2025[1] Market Volatility - Great Wall Military Industry (601606) reported severe abnormal fluctuations on August 14, 2025[1] - Dongxin Co., Ltd. (688110) had an announcement on August 16, 2025, regarding market conditions[1] - Changfei Optical Fiber (601869) has an announcement dated August 27, 2025, related to market performance[1] Company Announcements - ST Dehao (002005) has an announcement on August 27, 2025, regarding its market status[1] - China Satellite (600118) announced updates on August 27, 2025[1] - ST Yizhong (603389) has an announcement dated August 26, 2025, regarding its market activities[1]

New Stock Issuance - The new stock issuance for Sanxie Electric (证券代码: 920100) is priced at 8.83[1] - Shenkou Co. (证券代码: 002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (证券代码: 600399) has a tender offer period from August 12, 2025, to September 10, 2025[1] Market Alerts - Changcheng Military Industry (证券代码: 601606) is experiencing severe abnormal fluctuations[1] - ST Yanzhen (证券代码: 603389) has reported significant trading anomalies[1] - ST Zhongdi (证券代码: 000609) has been flagged for unusual trading activity[1] Other Notable Stocks - Zhanjiang Development (证券代码: 000753) and Pudong Construction (证券代码: 600284) are also under scrutiny for trading irregularities[1] - The stock of Zhaoyi Innovation (证券代码: 603986) is being monitored for potential volatility[1] - The stock of ST Suwu (证券代码: 600200) has been highlighted for its trading behavior[1]

Group 1 - The core point of the announcement is that Sinomed has received a medical device registration certificate for its subsidiary's product, a disposable microcatheter, from the National Medical Products Administration [2][3] - The product is designed for general vascular operations, including the infusion of diagnostic agents and appropriate devices [2][3] - The microcatheter is a single-lumen device with a semi-rigid proximal part and a flexible distal part, featuring a hydrophilic coating to reduce friction during vascular operations [3] Group 2 - The registration certificate for the disposable microcatheter is valid until August 21, 2030, and the product has a shelf life of two years [3] - This product is part of the third category of medical devices, and further production licensing is required before it can be manufactured [4] - The approval of this product is expected to enhance the company's product portfolio in the neurointerventional sector and improve its market competitiveness [4] Group 3 - The company plans to hold a half-year performance briefing on September 3, 2025, to engage with investors and address their concerns [7][8] - The briefing will be conducted online through the Shanghai Stock Exchange Roadshow Center, allowing investors to submit questions in advance [10][12] - Key personnel, including the chairman and financial director, will participate in the briefing to provide insights and answer investor inquiries [9]

截至2025年8月25日收盘，赛诺医疗股价报33.38元，较前一交易日上涨0.68元，涨幅2.08%。当日成交 额23.07亿元，换手率16.47%。 赛诺医疗属于医疗器械行业，专注于高端介入医疗器械的研发、生产和销售。公司主要产品包括冠脉支 架、球囊导管等，其控股子公司赛诺神畅医疗科技有限公司近日获得国家药监局颁发的一次性使用微导 管医疗器械注册证，该产品适用于神经血管内操作。 风险提示：市场有风险，投资需谨慎。 来源：金融界 消息面上，赛诺医疗公告称，其子公司获得一次性使用微导管注册证，注册证有效期至2030年8月21 日。此外，公司2025年中期实现营收2.40亿元，归母净利润1384万元。 资金流向方面，8月25日主力资金净流出1.07亿元，近五日主力资金累计净流出14.54亿元。 ...

Company Overview - Sino Medical (SH 688108) announced on August 25 that its subsidiary, Sino Shenchang Medical Technology Co., Ltd., received the Medical Device Registration Certificate from the National Medical Products Administration for its product "Disposable Microcatheter" [1] - As of the announcement, Sino Medical's market capitalization stands at 13.9 billion yuan [1] Revenue Composition - For the year 2024, Sino Medical's revenue composition is as follows: 99.83% from the medical device industry and 0.17% from other businesses [1]

New Stock Issuance - New stock issuance for Huaxin Jingke at a price of 18.60 on August 25, 2025[1] - Shenkou Co. (stock code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Market Alerts - Dongxin Co. (stock code: 688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (stock code: 600200) and ST Zhongdi (stock code: 000609) both have announcements dated August 25, 2025[1] - Multiple companies including Zhehai Deman (stock code: 688577) and Huaguang Huaneng (stock code: 600475) have announcements related to abnormal fluctuations on August 23, 2025[1] Additional Information - The report includes links to detailed announcements for various companies, providing transparency and access to further information[1] - The document highlights the importance of monitoring stock performance and market trends for informed investment decisions[1]

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-040 赛诺医疗科学技术股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、说明会类型 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2025 年 08 月 22 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司 2025 年半年度报告》及其摘要。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解公司，在上 海证券交易所的支持下，公司计划于 2025 年 09 月 03 日 16:00-17:00 在上证路 演中心（网址：https://roadshow.sseinfo.com/）以网络文字互动问答的方式 举行赛诺医疗 2025 年半年度业绩说明会，与广大投资者进行充分交流，解答投 资者普遍关注的问题。 二、说明会召开的时间、地点 1、会议召开时间：2025 年 09 月 03 日 16:0 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-039 赛诺医疗科学技术股份有限公司关于 子公司产品获得国内医疗器械注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）控股子公 司赛诺神畅医疗科技有限公司（以下简称"赛诺神畅"）收到国家药品监督管理局（以下 简称"国家药监局"）颁发的《中华人民共和国医疗器械注册证》，现将相关情况公告如 下： 适用范围：该产品用于一般性血管内操作，包括在神经血管内输注诊断性制剂(造 影剂)和适当的器械(弹簧圈、支架)。 有效期至：2030 年 8 月 21 日 二、医疗器械基本情况 本次获得《医疗器械注册证》的一次性使用微导管，是由公司控股子公司赛诺神畅 自主研发并进行生产的一款导管产品。该产品为单腔器械，有半刚性的近端部分和柔韧 的远端部分。微导管手柄上有鲁尔接头可以用来连接附件。微导管远端有不透射线标记， 可以在 X 射线下清晰可辨。微导管外表面涂有亲水涂层，能减少血管 ...

Financial Performance - In the first half of 2025, the company achieved revenue of 240 million (up 12.53% year-on-year), net profit attributable to shareholders of 14 million (up 296.54%), and net profit excluding non-recurring items of 8 million (up 163.35%) [1] - In Q2 2025, the company reported revenue of 140 million (up 13.86%), net profit attributable to shareholders of 11 million (up 110.56%), and net profit excluding non-recurring items of 7 million (up 42.83%) [1] Product Development and Market Expansion - The company is successfully advancing its coronary intervention consumables both domestically and internationally, with steady sales growth in coronary stents and balloons participating in national and provincial procurement [2] - As of August 22, 2025, the second round of volume-based procurement for coronary stents has been executed in most provinces, and the company has completed follow-up procurement for coronary balloons in most regions [2] - The company’s coronary drug-eluting stent system has received overseas registration in countries such as Argentina, Ecuador, and Vietnam, while its coronary balloon products have been registered in Kyrgyzstan, Peru, and Malaysia, expanding its international sales footprint [2] Regulatory Approvals and Innovations - The company received FDA notification for its self-expanding drug-coated intracranial stent system and COMEX balloon microcatheter, which have been granted Breakthrough Device Designation, marking a significant milestone as the first product of its kind for treating intracranial atherosclerosis [3] - The company’s subsidiary has also developed a flow-directed mesh stent that received medical device registration in China and is under CE registration review in Europe [3] Profit Forecast and Investment Rating - Due to increased expenses for new product promotion and R&D, the company has revised its net profit forecasts for 2025-2026 down to 31 million and 58 million respectively, with an expected net profit of 80 million for 2027 [3] - The corresponding PE ratios based on current market capitalization are projected to be 433, 234, and 170 times for the respective years, maintaining a "buy" rating considering the anticipated domestic launch of the intracranial self-expanding drug-coated stent [3]